The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Osteopontin Identified as Lead Marker of Colon Cancer Progression, Using Pooled Sample Expression Profiling
Open accessAbstract
BACKGROUND: New tumor markers and markers of tumor progression are needed for improved staging and for better assessment of treatment of many cancers. Gene expression profiling techniques offer the opportunity to discover such markers. We investigated the feasibility of sample pooling strategy in combination with a novel analysis algorithm to identify markers. METHODS: Total RNA from human colon tumors (n = 60) of multiple stages (adenomas; cancers with modified Astler Collier stages B, C, and D; and liver metastases) were pooled within stages and compared with pooled normal mucosal specimens (n = 10) by using oligonucleotide expression arrays. Genes that showed consistent increases or decreases in their expression through tumor progression were identified. Northern blot analysis was used to validate the findings. All statistical tests were two-sided. RESULTS: More than 300 candidate tumor markers and more than 100 markers of tumor progression were identified. Northern analysis of 11 candidate tumor markers confirmed the gene expression changes. The gene for the secreted integrin-binding protein osteopontin was most consistently differentially expressed in conjunction with tumor progression. Its potential as a progression marker was validated (Spearman's rho = 0.903; P<.001) with northern blot analysis using RNA from an independent set of 10 normal and 43 tumor samples representing all stages. Moreover, a statistically significant correlation between osteopontin protein expression and advancing tumor stage was identified with the use of 303 additional specimens (human cancer = 185, adenomas = 67, and normal mucosal specimens = 51) (Spearman's rho = 0.667; P<.001). CONCLUSIONS: Sample pooling can be a powerful, cost-effective, and rapid means of identifying the most common changes in a gene expression profile. We identified osteopontin as a clinically useful marker of tumor progression by use of gene expression profiling on pooled samples.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cluster analysis and display of genome-wide expression patterns
Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 16,184
Use of a cDNA microarray to analyse gene expression patterns in human cancer
(1996) · Nature Genetics · doi:10.1038/ng1296-457 · Cited by 1,951
Notterman, D. A., Alon, U., Sierk, A. J., & Levine, A. J. (2001) · PubMed · Cited by 606
Moertel, C. G. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510080047030 · Cited by 449
Molecular profiling of human cancer
Liotta, L., & Petricoin, E. (2000) · Nature Reviews Genetics · doi:10.1038/35049567 · Cited by 446
Role of Osteopontin in Cellular Signaling and Toxicant Injury
Denhardt, D. T., Giachelli, C. M., & Rittling, S. R. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.723 · Cited by 349
Osteopontin expression and distribution in human carcinomas.
Brown, L. F., Papadopoulos-Sergiou, A., Berse, B., Manseau, E. J., Tognazzi, K., Perruzzi, C. A., Dvorak, H. F., & Senger, D. R. (1994) · PubMed Central · Cited by 329
Vargas-Roig, L. M., Gago, F. E., Tello, O. M., Aznar, J. C., & Ciocca, D. R. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19981023)79:5<502::aid-ijc10>3.0.co;2-3 · Cited by 302
Osteopontin: possible role in prostate cancer progression.
Thalmann, G. N., Sikes, R. A., Devoll, R. E., Kiefer, J., Markwalder, R. V., Klima, I., Farach‐Carson, M. C., Studer, U. E., & Chung, L. W. K. (1999) · PubMed · Cited by 261
The Functional and Clinical Roles of Osteopontin in Cancer and Metastasis
Furger, K. A., Menon, R. K., Tuck, A. B., Bramwell, V. H. C., & Chambers, A. F. (2001) · Current Molecular Medicine · doi:10.2174/1566524013363339 · Cited by 217
Cited by
TM4: a free, open-source system for microarray data management and analysis
Saeed, A. I., Sharov, V., White, J., Li, J., Liang, W., Bhagabati, N., Braisted, J., Klapa, M., Currier, T., Thiagarajan, M., et al. (2003) · BioTechniques · doi:10.2144/03342mt01 · Cited by 4,837
Colon Cancer Survival Rates With the New American Joint Committee on Cancer Sixth Edition Staging
O'Connell, J. B., Maggard, M. A., & Ko, C. Y. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh275 · Cited by 1,599
Hypoxic gene expression and metastasis
Le, Q.-T., Denko, N. C., & Giaccia, A. J. (2004) · Cancer and Metastasis Reviews · doi:10.1023/b:canc.0000031768.89246.d7 · Cited by 468
Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer
Bellahcène, A., Castronovo, V., Ogbureke, K. U. E., Fisher, L. W., & Fedarko, N. S. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2345 · Cited by 454
Jorissen, R. N., Gibbs, P., Christie, M., Prakash, S., Lipton, L., Desai, J., Kerr, D., Aaltonen, L. A., Arango, D., Kruhøffer, M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1431 · Cited by 437
Metadata
- Authors
- Agrawal, D.
- Venue
- CancerSpectrum Knowledge Environment
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-04-03
- Volume
- 94
- Issue
- 7
- Pages
- 513-521
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2153206163
- Cited by
- 413
- References
- 15
- FWCI
- 19.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Osteopontin Identified as Lead Marker of Colon Cancer Progression, Using Pooled Sample Expression Profiling. https://app.cochat.ai/papers/10.1093/jnci/94.7.513
- The paper
- Agrawal, D. (2002). Osteopontin Identified as Lead Marker of Colon Cancer Progression, Using Pooled Sample Expression Profiling. CancerSpectrum Knowledge Environment. https://doi.org/10.1093/jnci/94.7.513
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.